Quantcast

Latest Oncotype DX Stories

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...

2014-09-26 08:25:45

Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif., Sept. 26, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ) will be featured as an oral presentation at the 37(th) Annual...

2014-09-24 08:27:58

Prostate Cancer Survivor Joe Torre, Three Prominent Advocacy Organizations and Genomic Health Partner to Encourage Men to Seek Genomic Testing to Enable More Confident Treatment Decisions and Avoid Life-altering Side Effects REDWOOD CITY, Calif., Sept. 24, 2014 /PRNewswire/ -- In partnership with Men's Health Network (MHN), Prostate Health Education Network (PHEN), ZERO - the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor,...

2014-09-12 08:23:43

Results Suggest that Oncotype DX® Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of...

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an...

2014-08-08 08:26:06

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the 34(th) Annual Canaccord Growth Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET). http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the...

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-07-31 08:35:54

REDWOOD CITY, Calif., July 31, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 7 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of the second quarter financial results after market close. http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO Conference Call DetailsTo access the live conference call on...

2014-06-16 12:29:09

Approval to Begin Clinical Laboratory Operations in Support of PraediCare-Dx(TM) Portfolio CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- EUTROPICS Inc., a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, today announced its laboratory, located in Cambridge, MA, has received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services' Centers for...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related